Challenges and opportunities for new protein crystallization strategies in structure-based drug design

Structure-based drug design (SBDD) has emerged as a valuable pharmaceutical lead discovery tool, showing potential for accelerating the discovery process, while reducing developmental costs and boosting potencies of the drug that is ultimately selected. SBDD is an iterative, rational, lead compound sculpting process that involves both the synthesis of new derivatives and the evaluation of their binding to the target structure either through computational docking or elucidation of the target structure as a complex with the lead compound. This method heavily relies on the production of high-resolution (< 2 Å) 3D structures of the drug target, obtained through X-ray crystallographic analysis, in the presence or absence of the drug candidate. The lack of generalized methods for high quality crystal production is still a major bottleneck in the process of macromolecular crystallization. This review provides a brief introduction to SBDD and describes several macromolecular crystallization strategies, with an emphasis on advances and challenges facing researchers in the field today. Recent trends in the development of more universal macromolecular crystallization techniques, particularly nucleation-based techniques that are applicable to both soluble and integral membrane proteins, are also discussed.

[1]  Helen Song,et al.  Reactions in droplets in microfluidic channels. , 2006, Angewandte Chemie.

[2]  J. An,et al.  Structure-based virtual screening of chemical libraries for drug discovery. , 2006, Current opinion in chemical biology.

[3]  N. Chayen,et al.  New directions in conventional methods of protein crystallization. , 2009, Progress in biophysics and molecular biology.

[4]  Katrina Sleeman,et al.  Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease. , 2009, Journal of medicinal chemistry.

[5]  Fredrik Bergström,et al.  High Throughput Screening of Drug‐Protein Binding in Drug Discovery , 2007 .

[6]  W. F. Azevedo.  MolDock applied to structure-based virtual screening. , 2010 .

[7]  K. Lundstrom,et al.  Structural genomics for membrane proteins , 2006, Cellular and Molecular Life Sciences CMLS.

[8]  J. Rosenbusch,et al.  Lipidic cubic phases: a novel concept for the crystallization of membrane proteins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R A Milligan,et al.  Lipid nanotubes as substrates for helical crystallization of macromolecules. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Arseniev,et al.  Lipid-protein nanoscale bilayers: a versatile medium for NMR investigations of membrane proteins and membrane-active peptides. , 2008, Journal of the American Chemical Society.

[11]  Sarah L Perry,et al.  Microfluidic Generation of Lipidic Mesophases for Membrane Protein Crystallization. , 2009, Crystal growth & design.

[12]  A. Arseniev,et al.  Lipid-protein nanodiscs: Possible application in high-resolution NMR investigations of membrane proteins and membrane-active peptides , 2009, Biochemistry (Moscow).

[13]  Jie Zhang,et al.  Recent progress in rational drug design of neuraminidase inhibitors. , 2007, Current medicinal chemistry.

[14]  W. Leifert,et al.  G Protein-Coupled Receptors in Drug Discovery , 2009, Methods in Molecular Biology.

[15]  Martin Caffrey,et al.  Membrane protein crystallization. , 2003, Journal of structural biology.

[16]  David H. Thompson,et al.  Synthesis and Self-assembly Properties of Acylated Cyclodextrins and Nitrilotriacetic Acid (NTA)-modified Inclusion Ligands for Interfacial Protein Crystallization , 2005 .

[17]  T. Blundell,et al.  Structural biology and drug discovery. , 2005, Drug discovery today.

[18]  N. Chayen,et al.  Towards a 'universal' nucleant for protein crystallization. , 2009, Trends in biotechnology.

[19]  Arun K. Ghosh,et al.  Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy , 2006, Annual Reports in Medicinal Chemistry.

[20]  G. Oliva,et al.  Virtual screening and its integration with modern drug design technologies. , 2008, Current medicinal chemistry.

[21]  Peter Kolb,et al.  Docking screens: right for the right reasons? , 2009, Current topics in medicinal chemistry.

[22]  From surface self-assembly to crystallization: prediction of protein crystallization conditions. , 2006, The journal of physical chemistry. B.

[23]  S. Fuller,et al.  Organization of HIV-1 Capsid Proteins on a Lipid Monolayer* , 1998, The Journal of Biological Chemistry.

[24]  R. Ismagilov,et al.  Screening of protein crystallization conditions on a microfluidic chip using nanoliter-size droplets. , 2003, Journal of the American Chemical Society.

[25]  M. Mazumdar,et al.  Attempts to rationalize protein crystallization using relative crystallizability. , 2006, Journal of structural biology.

[26]  W. F. de Azevedo.  MolDock applied to structure-based virtual screening. , 2010, Current drug targets.

[27]  Liang Li,et al.  Laterally mobile, functionalized self-assembled monolayers at the fluorous-aqueous interface in a plug-based microfluidic system: characterization and testing with membrane protein crystallization. , 2009, Journal of the American Chemical Society.

[28]  R. Stevens,et al.  GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.

[29]  Bryan L Roth,et al.  Receptor systems: will mining the receptorome yield novel targets for pharmacotherapy? , 2005, Pharmacology & therapeutics.

[30]  R. Ismagilov,et al.  Protein crystallization using microfluidic technologies based on valves, droplets, and SlipChip. , 2010, Annual review of biophysics.

[31]  R. Stevens,et al.  High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. , 2007, Science.

[32]  Youcef Mehellou,et al.  Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? , 2010, Journal of medicinal chemistry.

[33]  S. Iwata,et al.  Advanced method for high-throughput expression of mutated eukaryotic membrane proteins in Saccharomyces cerevisiae. , 2008, Biochemical and biophysical research communications.

[34]  de Azevedo Wf.  Structure-based virtual screening. , 2010 .

[35]  Structural biology: A moving story of receptors , 2008, Nature.

[36]  J. Irwin,et al.  Docking and chemoinformatic screens for new ligands and targets. , 2009, Current opinion in biotechnology.

[37]  Walter Filgueira de Azevedo.  Structure-Based Virtual Screening , 2010 .

[38]  Peter Kolb,et al.  Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.

[39]  Naomi E Chayen,et al.  Optimization techniques for automation and high throughput. , 2007, Methods in molecular biology.

[40]  D. Thompson,et al.  Design, Synthesis, and Performance of NTA-modified Lipids as Templates for Histidine-tagged Protein Crystallization , 2007 .

[41]  B. Samuelsson,et al.  HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells. , 2010, Journal of medicinal chemistry.

[42]  Kenneth Lundstrom,et al.  An Overview on GPCRs and Drug Discovery: Structure-Based Drug Design and Structural Biology on GPCRs , 2009, Methods in molecular biology.

[43]  Xiang-yang Liu,et al.  Protein interactions in undersaturated and supersaturated solutions: a study using light and x-ray scattering. , 2003, Biophysical journal.

[44]  B. Rost,et al.  Understanding the physical properties that control protein crystallization by analysis of large-scale experimental data , 2009, Nature Biotechnology.

[45]  I. Kuntz.  Structure-Based Strategies for Drug Design and Discovery , 1992, Science.

[46]  Donald J Abraham,et al.  Structure-based drug design strategies in medicinal chemistry. , 2009, Current topics in medicinal chemistry.

[47]  Richard A. Lewis,et al.  Three-dimensional pharmacophore methods in drug discovery. , 2010, Journal of medicinal chemistry.

[48]  Chad A Mirkin,et al.  The Controlled Evolution of a Polymer Single Crystal , 2005, Science.

[49]  S. Sligar,et al.  Direct solubilization of heterologously expressed membrane proteins by incorporation into nanoscale lipid bilayers. , 2003, BioTechniques.

[50]  M. Navia,et al.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.

[51]  A. Kuglstatter,et al.  Acoustic matrix microseeding: improving protein crystal growth with minimal chemical bias. , 2010, Acta crystallographica. Section D, Biological crystallography.

[52]  Mark B Gerstein,et al.  Computational analysis of membrane proteins: the largest class of drug targets. , 2009, Drug discovery today.

[53]  B. Dittrich,et al.  Validation of experimental charge densities: refinement of the macrolide antibiotic roxithromycin. , 2010, Acta crystallographica. Section B, Structural science.

[54]  S. Sligar,et al.  Membrane protein assembly into Nanodiscs , 2010, FEBS letters.

[55]  L. Mayr,et al.  Optimization of protein expression systems for modern drug discovery , 2007, Expert review of proteomics.

[56]  M. Schmid,et al.  Structural analysis of membrane‐bound retrovirus capsid proteins , 1997, The EMBO journal.

[57]  Chapter 8 Advances in Microfluidic Membrane Protein Crystallization Techniques , 2009 .

[58]  Mark von Itzstein,et al.  The war against influenza: discovery and development of sialidase inhibitors. , 2007, Nature reviews. Drug discovery.

[59]  V. Cherezov,et al.  Rational design of lipid for membrane protein crystallization. , 2004, Journal of structural biology.

[60]  Rustem F Ismagilov,et al.  Using nanoliter plugs in microfluidics to facilitate and understand protein crystallization. , 2005, Current opinion in structural biology.